Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma, Follicular 23Lymphoma, Non-Hodgkin 17Lymphoma, Mantle-Cell 16Lymphoma, Large B-Cell, Diffuse 15Lymphoma 14Lymphoma, B-Cell, Marginal Zone 12Lymphoma, B-Cell 8Recurrence 7Neoplasms 6Burkitt Lymphoma 5Leukemia, B-Cell 4Neoplasm, Residual 3Leukemia, Hairy Cell 2Leukemia 2Dendritic Cell Sarcoma, Interdigitating 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Mesothelioma 1Melanoma 1Mature B-cell Malignancies 1Mature B-Cell Malignancies 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Prolymphocytic 1

Interventions

zanubrutinib 1tislelizumab 1tirabrutinib 1obinutuzumab 1itacitinib 1idelalisib 1INCB039110 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
B-cell Malignancies × obinutuzumab × 1 year × Clear all
NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Gilead Sciences

Phase 1 Terminated
203 enrolled 43 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡